Cytosorbents Corporation (CTSO) News

Cytosorbents Corporation (CTSO): $2.25

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CTSO News Items

CTSO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CTSO News Highlights

  • For CTSO, its 30 day story count is now at 5.
  • Over the past 23 days, the trend for CTSO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CTSO are DECK and PROF.

Latest CTSO News From Around the Web

Below are the latest news stories about Cytosorbents Corp that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

Cytosorbents (CTSO) Presents At Annual SVB Leerink Global Health Conference

The following slide deck was published by Cytosorbents Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | February 24, 2022

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.

Yahoo | February 8, 2022

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.

Yahoo | February 3, 2022

CytoSorbents says patient enrollment begins in PROCYSS trial of CYtoSorb for septic shock

CytoSorbents (NASDAQ:CTSO) said the first patient was enrolled in the PROCYSS trial evaluating CYtoSorb to reverse refractory septic shock (RSS). RSS is a persistent and potentially fatal drop in blood pressure despite fluid resuscitation and high dose vasopressor use, seen in patients with life-threatening infection and sepsis. The company said...

Seeking Alpha | February 1, 2022

First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the PROCYSS (Prospective, Randomized, controlled trial with use Of CYtoSorb® to reverse refractory Septic Shock) trial in Germany by Prof. Dr. Stefan Kluge, Director, Department of Intensive Care Medicine at the Univers

Yahoo | February 1, 2022

New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights a new publication in the peer-reviewed journal, Annals of Thoracic and Cardiovascular Surgery, entitled "Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations." In this publication, Hassan et al. reported on the use of intraoperative hemoadsorption using CytoSorbents' technolog

Yahoo | January 24, 2022

CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds

CytoSorbents Corp (NASDAQ: CTSO ) reported preliminary Q4 FY21 revenue of approximately $10.8 million , better than the consensus of $9.58 million. It reported revenue of $12.0 million in Q4 2020. The company expects blended product gross margins to be approximately 80% for Q4 Full story available on Benzinga.com

Benzinga | January 18, 2022

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, issues a stockholder letter from its Chief Executive Officer, Dr. Phillip Chan, and announces preliminary unaudited fourth quarter 2021 and full year 2021 results ahead of filing its Form 10-K.

Yahoo | January 18, 2022

Do Insiders Own Lots Of Shares In Cytosorbents Corporation (NASDAQ:CTSO)?

If you want to know who really controls Cytosorbents Corporation ( NASDAQ:CTSO ), then you'll have to look at the...

Yahoo | January 12, 2022

Dawson James Remains a Buy on Cytosorbents (CTSO)

Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO – Research Report) on November 22 and set a price target of $16.00. The company's shares closed last Tuesday at $4.03. According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Currently, the analyst consensus on Cytosorbents is a Strong Buy with an average price target of $12.75.

Howard Kim on TipRanks | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5608 seconds.